References
- BieloryLAllergic and immunologic disorders of the eye. Part II: ocular allergyJ Allergy Clin Immunol200010661019103211112882
- BurbachGJHeinzerlingLMRöhneltCRagweed sensitization in Europe – GA(2)LEN study suggests increasing prevalenceAllergy200964466466519210367
- La RosaMLionettiEReibaldiMAllergic conjunctivitis: a comprehensive review of the literatureItal J Pediatr201339181823497516
- BaconASAhluwaliaPIraniAMTear and conjunctival changes during the allergen-induced early- and late-phase responsesJ Allergy Clin Immunol2000106594895411080719
- CiprandiGBuscagliaSPesceGPBagnascoMCanonicaGWOcular challenge and hyperresponsiveness to histamine in patients with allergic conjunctivitisJ Allergy Clin Immunol1993916122712308099594
- EhlersWHDonshikPCAllergic ocular disorders: a spectrum of diseasesClao J19921821171241606674
- GomesPJTrends in prevalence and treatment of ocular allergyCurr Opin Allergy Clin Immunol201414545145625115683
- AbelsonMBChambersWASmithLMConjunctival allergen challenge. A clinical approach to studying allergic conjunctivitisArch Ophthalmol1990108184882297337
- NakataniHAlcaftadine 0.25% versus olopatadine 0.1% in preventing cedar pollen allergic conjunctivitis in JapanA Randomized Study2018
- MclaurinENarvekarAGomesPAdewaleATorkildsenGPhase 3 randomized double-masked study of efficacy and safety of once-daily 0.77% olopatadine hydrochloride ophthalmic solution in subjects with allergic conjunctivitis using the conjunctival allergen challenge modelCornea201534101245125126266427
- MclaurinEBergmannMNarvekarAAdewaleAGomesPJTorkildsenGPooled analysis of two studies evaluating efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitisClinical Ophthalmology (Auckland, NZ.)20171110891097
- TorkildsenGAbelsonMBGomesPJMclaurinEPottsSLMahFSvehicle-controlled, Phase 2 clinical trial of a sustained-release dexamethasone intracanalicular insert in a chronic allergen challenge modelJ Ocul Pharmacol Ther2017332799028072552
- CavetMEGomesPJCarrWWWilliamsJIBepotastine besilate ophthalmic solution 1.5% for alleviating nasal symptoms in patients with allergic conjunctivitisJ Asthma Allergy201811293929615844
- AbelsonMBShettySKorchakMButrusSISmithLMAdvances in pharmacotherapy for allergic conjunctivitisExpert Opin Pharmacother20151681219123125943976
- Johnson & Johnson Consumer Companies IZyrtec The #1 Allergist Recommended Brand* Available from: http://www.multivu.com/assets/52078/documents/Zyrtec-fact-sheet-99-original.pdf2011
- FDAPerscribing Information for Zerviate TM Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208694s000lbl.pdf2017
- ZhangLChengLHongJThe clinical use of cetirizine in the treatment of allergic rhinitisPharmacology2013921–2142523867423
- PortnoyJMDinakarCReview of cetirizine hydrochloride for the treatment of allergic disordersExpert Opin Pharmacother20045112513514680442
- WhiteMVThe role of histamine in allergic diseasesJ Allergy Clin Immunol1990864 Pt 25996051699987
- LanierBQAbelsonMBBergerWEComparison of the efficacy of combined fluticasone propionate and olopatadine versus combined fluticasone propionate and fexofenadine for the treatment of allergic rhinoconjunctivitis induced by conjunctival allergen challengeClin Ther20022471161117412182260
- SpanglerDLAbelsonMBOberAGotnesPJRandomized, double-masked comparison of olopatadine ophthalmic solution, mometasone furoate monohydrate nasal spray, and fexofenadine hydrochloride tablets using the conjunctival and nasal allergen challenge modelsClin Ther20032582245226714512132
- NakataniHGomesPBradfordRGuoQSafyanEHollanderDAAlcaftadine 0.25% versus Olopatadine 0.1% in preventing cedar pollen allergic conjunctivitis in Japan: a randomized studyOcul Immunol Inflamm2018110
- MclaurinEBMarsicoNPAckermanSLOcular itch relief with alcaftadine 0.25% versus olopatadine 0.2% in allergic conjunctivitis: pooled analysis of two multicenter randomized clinical trialsAdv Ther201431101059107125260889
- AckermanSD’AmbrosioFGreinerJVVillanuevaLCiolinoJBHollanderDAA multicenter evaluation of the efficacy and duration of action of alcaftadine 0.25% and olopatadine 0.2% in the conjunctival allergen challenge modelJ Asthma Allergy20136435224109191
- OnoSJAbelsonMBAllergic conjunctivitis: update on pathophysiology and prospects for future treatmentJ Allergy Clin Immunol2005115111812215637556